Quantcast
Channel: Nottingham Post Latest Stories Feed
Viewing all articles
Browse latest Browse all 10940

'Reject' cancer drug Gazyvaro gets all-clear

$
0
0

A CANCER drug tested at Nottingham's hospitals has come on to the market.

Health watchdog Nice has reversed its verdict on Gazyvaro. Patients with chronic lymphocytic leukaemia, the most common type of adult leukaemia, could soon have routine access to the drug, which can extend survival and remission times – just two months on from Nice's rejection of the drug.

Combined with chemotherapy, the drug can reduce the risk of death by 59 per cent and keep patients in remission more than 15 months longer than chemotherapy alone.


Viewing all articles
Browse latest Browse all 10940

Latest Images

Trending Articles



Latest Images

<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>